IVZ — Invesco Ltd.

The tape is constructive but the consensus is not: as of 2026-09-13 the stock had returned +11.6% over three months and +40.4% over six months, yet the sell-side consensus rating is Hold (12 buys / 16 holds / 0 sells) and the $32.80 average price target sits essentially on top of the $32.28 share price - meaning the market has already paid for the earnings recovery. Recent friction includes ~$1.46M of insider selling in September 2026, a Zacks downgrade to Hold, and a -2.39% week. Offsetting that: August 2026 showed $27.6B of net long-term inflows and $35.8B of money-market inflows, total AUM reached $2.56 trillion, and bulls like KBW ($39 target) argue the QQQ ETF conversion economics and operating leverage are still underappreciated.

This is an inflection, not a blip. Revenue went $1.442B (Q3 2023) -> $1.483B (Q2 2024) -> $1.515B (Q2 2025) -> $1.826B (Q2 2026), and the YoY growth rate troughed at +6.2% in Q4 2025 before accelerating to +14.1% in Q1 2026 and +20.5% in Q2 2026 - the fastest growth in the three-year window. Operating margin tells the same story: 14.1% in Q2 2025, 16.5% in Q3 2025, 19.1% in Q1 2026, 20.0% in Q2 2026, roughly +580bps YoY. Net income doubled YoY in Q2 2026 ($382.3M vs $203.4M). The two ugly quarters in the dataset - Q4 2023 (-$1.076B operating income) and Q4 2025 (-$1.458B operating income, -$2.61 EPS) - are non-cash goodwill/intangible impairments that coincided with healthy cash generation ($674M and $432M of FCF respectively); they are accounting resets, not operating deterioration. Free cash flow has compounded alongside: ~$1.11B in 2024, ~$1.44B in 2025, and ~$1.94B on a trailing-four-quarter basis through Q2 2026, with the usual Q1 seasonal drain (-$108M in Q1 2025, -$75M in Q1 2024). Caveat: the quarterly gross-profit line in the data is internally inconsistent (Q2 2026 gross profit of $1.818B on $1.826B of revenue vs ~35% margins in earlier quarters), so operating margin is the more reliable signal.

Fair, leaning fully valued after the run. As of 2026-09-13 at $32.28, IVZ trades at ~11.5x the FY2026 consensus EPS of $2.814 and ~10.4x a rough FY2027 estimate of ~$3.10 - almost exactly the 3-year average P/E of 11.48x, i.e. no discount left. The 2.07x P/S looks rich against a 5-year average of 1.5x, but that gap is largely a margin story (operating margin expanding from ~14% to ~20%) rather than pure multiple inflation. On P/B of 1.17x against ~$28.14 of book value per share, a return to ~$2.81 of EPS implies roughly a 10% ROE - fair, not cheap, for an asset manager with beta 1.605. The trailing P/E of -47.5 and PEG of 0.122 are meaningless artifacts of the impairment/negative TTM EPS and should be ignored; the forward multiple is the only usable lens here. Dividend yield of 2.61% (about $0.84/share) is a legitimate support, and a ~12-13% FCF yield on $1.94B of TTM free cash flow is the single strongest value argument in the data.

The price has already done the re-rating that the earnings are only now confirming: IVZ ran from roughly $23 to $32.28 in six months while TTM EPS was still negative, which means the market pre-paid for the recovery to ~$2.81 in FY2026 and ~$3.10 in FY2027. At ~11.5x forward earnings the stock is priced for 'the improvement is real and roughly this size' - it is not priced for upside surprises. The practical playbook: track the monthly preliminary AUM prints (August 2026's $27.6B of net long-term inflows is the number that must persist) and the Q3 2026 adjusted EPS against the ~$0.75 consensus on 2026-10-27. Beating on EPS while flows decelerate would likely knock the stock back toward the mid-$20s; flows accelerating would be the one thing that justifies paying above the historical multiple. Watch the spread between GAAP and adjusted results too - two goodwill impairments in three years (Q4 2023 and Q4 2025) means reported EPS will keep lurching in quarters where the non-cash charges land.

Trending higher but pausing. As of 2026-09-13: RSI(14) of 53.27 is dead-neutral (no overbought/oversold signal); price is 0.42% BELOW its 20-day SMA (~$32.42), 4.51% ABOVE its 50-day SMA (~$30.88) and 17.70% ABOVE its 200-day SMA (~$27.43) - a textbook strong-uptrend-with-short-term-consolidation setup. The 52-week range is $20.67-$33.66, so the stock sits ~4% below its high, and the one-week return is -2.39% after +2.35% (1mo), +11.62% (3mo) and +40.35% (6mo). Implication: this is not a chase point and not a capitulation buy. A pullback into the high-$29s/low-$30s (near the 50-day) would offer a materially better entry with the 200-day trend still intact; a decisive close below the 50-day (~$30.88) would be the first real warning that the six-month trend has rolled over.

• AUM-linked revenue: Invesco's top line is a direct function of market levels, so S&P 500 and especially QQQ/mega-cap tech performance flow straight into management fees - the stock is a leveraged play on equity markets with beta of 1.605.
• Rate cycle and money markets: elevated yields drove enormous money-market inflows ($35.8B in August 2026 alone), but a Fed easing path would compress money-market fee revenue and could reverse those balances even as it helps risk assets.
• Structural fee compression and the active-to-passive migration: the mix shift toward ETFs means higher volumes at lower fee rates, so AUM growth does not translate one-for-one into revenue growth.
• ETF share-class/conversion regulation and periodic SEC rulemaking on money-market funds and ETF relief - the QQQ open-end fund conversion that lifted Q2 2026 economics was a regulatory/structural event that could be extended or curtailed.
• Sector rotation and financials-beta: high-beta asset managers get amplified in both directions when capital rotates into or out of financials, independent of company-specific fundamentals.

• Q3 2026 earnings on 2026-10-27, with consensus EPS around $0.75 - the margin trajectory and organic flow commentary will determine whether the 20% revenue growth rate is durable.
• Monthly preliminary AUM disclosures (early each month): August 2026 showed $2.56T of AUM, +$27.6B of net long-term inflows and +$35.8B of money-market inflows - continuation or reversal is the best high-frequency tell on this thesis.
• Continued capital return and deleveraging: $50M of buybacks and >$450M of net debt reduction in Q2 2026, on top of a 2.61% dividend yield - more of the same would support EPS and sentiment.
• ETF franchise momentum, including the Invesco S&P 500 Equal Weight ETF (RSP) passing $100B in assets and the QQQ open-end fund conversion continuing to lift management fee economics.
• Insider activity: a ~$1.46M executive/director sale in September 2026; further selling would be a sentiment headwind, while open-market buying would be a meaningful signal.

• Double exposure to an equity drawdown: a 15-20% market correction would cut revenue directly (AUM-linked fees) AND compress the multiple simultaneously, which is exactly the scenario a beta of 1.605 magnifies.
• Structural fee compression and thin-margin improvement: the operating leverage that took margins from ~14% to ~20% cuts both ways - if ETF and money-market inflows slow, the fixed cost base becomes a problem fast.
• GAAP earnings quality and goodwill: two large Q4 impairments in three years (Q4 2023 and Q4 2025) show that the intangibles supporting $12.47B of stockholders' equity can be written down again; trailing GAAP ROIC of -1.2% is the formula's honest reminder of that.
• No valuation cushion left: P/S of 2.07x vs. a 5-year average of 1.5x, price ~4% below its 52-week high after a 40% six-month run, and an average analyst target of $32.80 that implies essentially zero upside from $32.28.
• Concentration risk in QQQ and mega-cap tech - the firm's flagship ETF franchise makes Invesco unusually sensitive to a tech-led selloff relative to diversified peers; balance-sheet reporting also shows long-term debt swinging between ~$1.6B and ~$10.5B across recent filings, which complicates leverage analysis.

Invesco's operating turnaround is real and better than the deterministic score implies: revenue growth accelerated to +20.5% YoY, operating margin expanded ~580bps to ~20%, TTM free cash flow reached ~$1.94B (a >13% FCF yield on a $14.3B market cap), and AUM of $2.56T with positive organic inflows is a genuine change from years of outflows. But as of 2026-09-13 the stock has already re-rated 40% in six months and trades at ~11.5x forward EPS - right on its own 3-year average and right on the sell-side consensus target - so the reward for taking on a beta-1.605 asset manager with a structurally challenged active book is now balanced. Own it for the 2.6% dividend and flow momentum if you already hold it, but from $32.28 the risk/reward is symmetric, and the smarter entry is a pullback toward the ~$30.9 50-day moving average.

Weighted blend of two methods as of 2026-09-13: (1) 12.0x forward P/E - a modest premium to Invesco's 3-year average of 11.48x, justified by the revenue and margin inflection - applied to a blended FY2026/FY2027 EPS of ~$2.93 (consensus FY26 $2.814 grown ~10%), giving ~$35.2; and (2) a normalized FCF cross-check on ~$1.7B of sustainable free cash flow (the midpoint of FY2025's $1.44B and the $1.94B TTM, since Q2 2026's $720M benefited from working-capital swings) at a 12% required yield across 443M shares, giving ~$32.0. Weighting the earnings multiple 2:1 over the FCF check - because the FCF base is flattered by non-cash amortization and working-capital timing - yields (2 x $35.16 + $31.96) / 3 = ~$34.09, rounded to $34.00, which equates to 12.1x FY26E EPS, 11.0x FY27E EPS, and an ~11% FCF yield.